At the intersection of medicine and governance, recent events have exposed a fragile infrastructure supporting the US pharmaceutical system. Regulatory agencies once viewed as technocratic strongholds now find themselves entangled in political reshuffling, leadership voids, and legal uncertainty.
The FDA’s inaction on vaccine approval, the FTC’s paralyzed insulin price lawsuit,